These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 5086393)

  • 1. Molecular structure of LSD.
    Baker RW; Chothia C; Pauling P; Weber HP
    Science; 1972 Nov; 178(4061):614-5. PubMed ID: 5086393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular structures of hallucinogenic substances: lysergic acid diethylamide, psilocybin, and 2,4,5-trimethoxyamphetamine.
    Baker RW; Chothia C; Pauling P; Weber HP
    Mol Pharmacol; 1973 Jan; 9(1):23-32. PubMed ID: 4685449
    [No Abstract]   [Full Text] [Related]  

  • 3. Interactions between lysergic acid diethylamide and dopamine-sensitive adenylate cyclase systems in rat brain.
    Hungen KV; Roberts S; Hill DF
    Brain Res; 1975 Aug; 94(1):57-66. PubMed ID: 238721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steric and electronic relationships among some hallucinogenic compounds.
    Kang S; Green JP
    Proc Natl Acad Sci U S A; 1970 Sep; 67(1):62-7. PubMed ID: 5272329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discriminative stimulus properties of lysergic acid diethylamide in the monkey.
    Nielsen EB
    J Pharmacol Exp Ther; 1985 Jul; 234(1):244-9. PubMed ID: 4009503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysergic acid diethylamide (LSD) and lisuride: differentiation of their neuropharmacological actions.
    White FJ; Appel JB
    Science; 1982 Apr; 216(4545):535-7. PubMed ID: 7071600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysergic acid diethylamide (LSD-25) antagonists. II. Development of tolerance in man to LSD-25 by prior administration of MLD-41 (1-methyl-d-lysergic acid diethylamide).
    ABRAMSON HA; SKLAROFSKY B; BARON MO; FREMONT-SMITH N
    AMA Arch Neurol Psychiatry; 1958 Feb; 79(2):201-7. PubMed ID: 13497364
    [No Abstract]   [Full Text] [Related]  

  • 8. Hyperthermic effects of D-lysergic acid diethylamide (LSD) and its derivatives in rabbits and rats.
    Hashimoto H; Hayashi M; Nakahara Y; Niwaguchi T; Ishii H
    Arch Int Pharmacodyn Ther; 1977 Aug; 228(2):314-21. PubMed ID: 303504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unsurmountable antagonism of brain 5-hydroxytryptamine2 receptors by (+)-lysergic acid diethylamide and bromo-lysergic acid diethylamide.
    Burris KD; Sanders-Bush E
    Mol Pharmacol; 1992 Nov; 42(5):826-30. PubMed ID: 1359397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual actions of lysergic acid diethylamide tartrate (LSD), 2-bromo-D-lysergic acid diethylamide bitartrate (BOL) and methysergide on dorsal root potentials evoked by stimulation of raphe nuclei.
    Larson AA; Chinn C; Proudfit HK; Anderson EG
    J Pharmacol Exp Ther; 1981 Apr; 217(1):99-104. PubMed ID: 6110778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advantages of analyzing postmortem brain samples in routine forensic drug screening-Case series of three non-natural deaths tested positive for lysergic acid diethylamide (LSD).
    Mardal M; Johansen SS; Thomsen R; Linnet K
    Forensic Sci Int; 2017 Sep; 278():e14-e18. PubMed ID: 28803722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal learning enhanced by lysergic acid diethylamide (LSD): concomitant rise in brain 5-hydroxytryptamine levels.
    King AR; Martin IL; Melville KA
    Br J Pharmacol; 1974 Nov; 52(3):419-26. PubMed ID: 4458849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Differences in the pharmacological effect of hallucinogenic and von-hallucinogenic lysergic acid derivatives (LSD 25, deseril, lysenyl, mesenyl)].
    Votava Z; Podvalová I; Vojtĕchovský M
    Arzneimittelforschung; 1966 Feb; 16(2):220-2. PubMed ID: 6014083
    [No Abstract]   [Full Text] [Related]  

  • 14. The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT
    De Gregorio D; Posa L; Ochoa-Sanchez R; McLaughlin R; Maione S; Comai S; Gobbi G
    Pharmacol Res; 2016 Nov; 113(Pt A):81-91. PubMed ID: 27544651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complex discriminative stimulus properties of (+)lysergic acid diethylamide (LSD) in C57Bl/6J mice.
    Benneyworth MA; Smith RL; Barrett RJ; Sanders-Bush E
    Psychopharmacology (Berl); 2005 Jun; 179(4):854-62. PubMed ID: 15645221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of hydrophobicity in the antiserotonin activity of LSD analogs.
    Dunn WJ; Bederka JP
    Res Commun Chem Pathol Pharmacol; 1974 Feb; 7(2):275-85. PubMed ID: 4818374
    [No Abstract]   [Full Text] [Related]  

  • 17. Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role?
    Whelan A; Johnson MI
    Pain Manag; 2018 May; 8(3):217-229. PubMed ID: 29722608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonist properties of d-LSD at 5-hydroxytryptamine2 receptors.
    Pierce PA; Peroutka SJ
    Neuropsychopharmacology; 1990; 3(5-6):503-8. PubMed ID: 2078283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of lysergic acid diethylamide (LSD) in urine by gas chromatography-ion trap tandem mass spectrometry.
    Sklerov JH; Kalasinsky KS; Ehorn CA
    J Anal Toxicol; 1999 Oct; 23(6):474-8. PubMed ID: 10517553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects.
    Schmid Y; Enzler F; Gasser P; Grouzmann E; Preller KH; Vollenweider FX; Brenneisen R; Müller F; Borgwardt S; Liechti ME
    Biol Psychiatry; 2015 Oct; 78(8):544-53. PubMed ID: 25575620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.